ISU104, a human monoclonal antibody targeting ErbB3, is currently in a Phase I clinical trial aimed at assessing its safety, tolerability, and pharmacokinetics in patients with advanced solid tumors. The trial's dual-part design includes a dose-escalation phase to establish the recommended Phase II dose (RP2D) and a dose-expansion phase focusing on recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). Given the increasing interest in targeted therapies for solid tumors, ISU104 could position ISU Abxis Co., Ltd. favorably within a competitive landscape that includes established therapies like cetuximab. The trial's outcomes may provide critical insights into the drug's efficacy and safety profile, influencing future development strategies and potential partnerships.